Skip to content

ANI Pharmaceuticals ANIP Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies

Incyte logo
IncyteINCY

Segments

By segment

See full
Generics and Other$0
Rare Disease and Brands$0

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
ANI Pharmaceuticals (ANIP) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of -$182K in Q1 2026.
How has ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 increased by 98.5% year-over-year, from -$12.09M to -$182K.
What is the long-term trend for ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's business combination contingent consideration arrangements change in amount of contingent consideration liability1 has grown at a 180.6% compound annual growth rate (CAGR), from $500K to -$31.01M.
What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
This metric represents the periodic adjustment to the fair value of liabilities associated with earn-outs or milestone payments from past acquisitions. Changes in this value reflect management's updated expectations regarding the probability and timing of achieving specific performance targets post-acquisition. It serves as a key indicator of acquisition integration success and the accuracy of initial valuation models.